115 related articles for article (PubMed ID: 37597685)
1. Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell Transplantation.
Xu Z; Choi J; Cooper M; King J; Fiala MA; Liu J; Pusic I; Romee R; Cashen A; Jacoby MA; Stockerl-Goldstein K; Abboud C; Vij R; Uy G; Westervelt P; Walter MJ; DiPersio JF; Schroeder MA
Transplant Cell Ther; 2023 Nov; 29(11):699.e1-699.e9. PubMed ID: 37597685
[TBL] [Abstract][Full Text] [Related]
2. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
3. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Sahebi F; Eikema DJ; Koster L; Kroger N; Meijer E; van Doesum JA; Rovira M; Koc Y; Angelucci E; Blaise D; Sammassimo S; McDonald A; Arroyo CH; Sanchez JF; Forcade E; Castagna L; Stölzel F; Sanz J; Tischer J; Ciceri F; Valcarcel D; Proia A; Hayden PJ; Beksac M; Yakoub-Agha I; Schönland S
Transplant Cell Ther; 2021 Dec; 27(12):999.e1-999.e10. PubMed ID: 34543768
[TBL] [Abstract][Full Text] [Related]
4. Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial.
Reshef R; Ganetsky A; Acosta EP; Blauser R; Crisalli L; McGraw J; Frey NV; Hexner EO; Hoxie JA; Loren AW; Luger SM; Mangan J; Stadtmauer EA; Mick R; Vonderheide RH; Porter DL
Biol Blood Marrow Transplant; 2019 Mar; 25(3):515-521. PubMed ID: 30315941
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).
Efebera YA; Geyer S; Andritsos L; Vasu S; Jaglowski S; Bingman A; Blum W; Klisovic R; Hofmeister CC; Benson DM; Penza S; Elder P; Cortright K; Kitzler R; Coombes K; O'Donnell L; Daneault B; Bradbury H; Zhang J; Chen X; Garman S; Ranganathan P; Yu X; Hofstetter J; Yu J; Garzon R; Scrape SR; Lozanski G; Devine SM
Biol Blood Marrow Transplant; 2016 Jan; 22(1):71-9. PubMed ID: 26256940
[TBL] [Abstract][Full Text] [Related]
6. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors.
Guru Murthy GS; Kim S; Hu ZH; Estrada-Merly N; Abid MB; Aljurf M; Bacher U; Badawy SM; Beitinjaneh A; Bredeson C; Cahn JY; Cerny J; Diaz Perez MA; Farhadfar N; Gale RP; Ganguly S; Gergis U; Hildebrandt GC; Grunwald MR; Hashmi S; Hossain NM; Kalaycio M; Kamble RT; Kharfan-Dabaja MA; Hamilton BK; Lazarus HM; Liesveld J; Litzow M; Marks DI; Murthy HS; Nathan S; Nazha A; Nishihori T; Patel SS; Pawarode A; Rizzieri D; Savani B; Seo S; Solh M; Ustun C; van der Poel M; Verdonck LF; Vij R; Wirk B; Oran B; Nakamura R; Scott B; Saber W
JAMA Oncol; 2022 Mar; 8(3):404-411. PubMed ID: 35024768
[TBL] [Abstract][Full Text] [Related]
7. Impact of Donor Statin Treatment on Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
Rashid N; Gooley T; Furlong T; Lee SJ; Martin PJ; Storb R; Mielcarek M
Transplant Cell Ther; 2023 Nov; 29(11):701.e1-701.e8. PubMed ID: 37657769
[TBL] [Abstract][Full Text] [Related]
8. A Calcineurin Inhibitor Free Graft Versus Host Disease Prophylaxis for Patients Undergoing Matched Related and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplant.
Iqbal M; Nieto FAM; Brannick KM; Li Z; Murthy H; Foran J; Roy V; Kharfan-Dabaja MA; Ayala E
Transplant Cell Ther; 2023 May; 29(5):327.e1-327.e9. PubMed ID: 36758832
[TBL] [Abstract][Full Text] [Related]
9. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
10. Triple-Drug Graft-versus-Host Disease Prophylaxis after HLA-Matched Unrelated Donor Nonmyeloablative Allogenic Hematopoietic Stem Cell Transplantation.
Wegener A; Andersen NS; Friis LS; Petersen SL; Schjødt I; Kornblit B; Sengeløv H; Gjærde LK
Transplant Cell Ther; 2023 Sep; 29(9):575.e1-575.e6. PubMed ID: 37301257
[TBL] [Abstract][Full Text] [Related]
11. Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation.
Rangarajan HG; Pereira MSF; Brazauskas R; St Martin A; Kussman A; Elmas E; Verneris MR; Gadalla SM; Marsh SGE; Paczesny S; Spellman SR; Lee SJ; Lee DA
Transplant Cell Ther; 2021 Nov; 27(11):926.e1-926.e10. PubMed ID: 34407489
[TBL] [Abstract][Full Text] [Related]
12. Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience.
Butera S; Cerrano M; Brunello L; Dellacasa CM; Faraci DG; Vassallo S; Mordini N; Sorasio R; Zallio F; Busca A; Bruno B; Giaccone L
Ann Hematol; 2021 Jul; 100(7):1837-1847. PubMed ID: 33948721
[TBL] [Abstract][Full Text] [Related]
13. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation.
Zhao Y; Shi J; Luo Y; Gao F; Tan Y; Lai X; Yu J; Wei G; Huang H
Biol Blood Marrow Transplant; 2020 May; 26(5):e128-e133. PubMed ID: 31982545
[TBL] [Abstract][Full Text] [Related]
14. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of graft-versus-host disease prophylaxis including bortezomib for allogeneic hematopoietic cell transplantation from unrelated donors with one or two HLA loci mismatches in Japanese patients.
Nakane T; Okamura H; Tagaito Y; Koh S; Yoshimura T; Makuuchi Y; Nanno S; Nakamae M; Hirose A; Nakashima Y; Koh H; Hino M; Nakamae H
Int J Hematol; 2019 Dec; 110(6):736-742. PubMed ID: 31560116
[TBL] [Abstract][Full Text] [Related]
16. Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts.
Jacob RP; Flynn J; Devlin SM; Maloy M; Giralt SA; Maslak P; O'Reilly RJ; Tonon JA; Perales MA; Avecilla ST; Cho C
Transplant Cell Ther; 2021 Aug; 27(8):697.e1-697.e5. PubMed ID: 33991721
[TBL] [Abstract][Full Text] [Related]
17. [The impact of donor-to-recipient gender compatibility on outcomes of haploid hematopoietic stem cell transplantation in patients with hematological malignancies].
Hu SS; Wu YB; Zhu PP; Shi JM; Yu J; Zhao YM; Lai XY; Liu LZ; Fu HR; Huang H; Luo Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):992-1002. PubMed ID: 36709104
[No Abstract] [Full Text] [Related]
18. Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study.
Ito A; Kim SW; Matsuoka KI; Kawakita T; Tanaka T; Inamoto Y; Toubai T; Fujiwara SI; Fukaya M; Kondo T; Sugita J; Nara M; Katsuoka Y; Imai Y; Nakazawa H; Kawashima I; Sakai R; Ishii A; Onizuka M; Takemura T; Terakura S; Iida H; Nakamae M; Higuchi K; Tamura S; Yoshioka S; Togitani K; Kawano N; Suzuki R; Suzumiya J; Izutsu K; Teshima T; Fukuda T
Int J Hematol; 2020 Nov; 112(5):674-689. PubMed ID: 32748216
[TBL] [Abstract][Full Text] [Related]
19. Clinical separation of cGvHD and GvL and better GvHD-free/relapse-free survival (GRFS) after unrelated cord blood transplantation for AML.
Zheng CC; Zhu XY; Tang BL; Zhang XH; Zhang L; Geng LQ; Liu HL; Sun ZM
Bone Marrow Transplant; 2017 Jan; 52(1):88-94. PubMed ID: 27376453
[TBL] [Abstract][Full Text] [Related]
20. ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation.
Pidala J; Tomblyn M; Nishihori T; Ayala E; Field T; Fernandez H; Perez L; Locke F; Alsina M; Ochoa JL; Perkins J; Tate C; Shapiro J; Conwell M; Bookout R; Anasetti C
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1237-44. PubMed ID: 21215811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
